Zobrazeno 1 - 10
of 14 873
pro vyhledávání: '"Anticancer Drug"'
Publikováno v:
Journal of Pharmacy & Pharmacognosy Research, Vol 12, Iss 5, Pp 881-891 (2024)
Context: Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer type, with 80-85% prevalence. Usually, NSCLC is treated by chemotherapy and radiotherapy in collaboration with gefitinib or other anticancer drugs. Those treatments have many
Externí odkaz:
https://doaj.org/article/d281cade0a684f1aaf223588fe0723d6
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Anticancer drugs may affect the incidence of dementia by modulating the common pathophysiology between cancer and dementia. However, there is a paucity of research that focused on anticancer drugs with different mechanisms of action and thei
Externí odkaz:
https://doaj.org/article/1240b1a4989e40babe89c6d0904f0b4e
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract Dimethyl 2-[2-(1-phenyl-4,5-dihydro-1H-imidazol-2-yl)hydrazinylidene]butanedioate (DIHB) and 8-(3-chlorophenyl)-2,6,7,8-tetrahydroimidazo[2,1-c][1,2,4]triazine-3,4-dione (HDIT) are promising candidates for anticancer agents, the first analyt
Externí odkaz:
https://doaj.org/article/ab3540a6c35a44e693cf136027d5ce67
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-15 (2024)
Abstract The size of the drug particles is one of the essential factors for the proper absorption of the drug compared to the dose of the drug. When particle size is decreased, drug uptake into the body increases. Recent studies have revealed that th
Externí odkaz:
https://doaj.org/article/a83fb9a57a5b4c3a977fef60862766c6
Autor:
Chen Zhang, Lingjiang Li
Publikováno v:
Alexandria Engineering Journal, Vol 97, Iss , Pp 8-13 (2024)
The determination of sunitinib (STB) as a significant anticancer drug is very important. In the present research, a novel and effective electrochemical sensing device for STB was manufactured using the modification of a glassy carbon electrode (GCE)
Externí odkaz:
https://doaj.org/article/9e4cb46f460540559a6ae68cdfcb88d1
Autor:
En Gao, Ya Wang, Gao-lu Fan, Guiqing Xu, Zi-Yuan Wu, Zi-Jun Liu, Jian-Cheng Liu, Long-Fei Mao, Xixi Hou, Shouhu Li
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract A series of 20 novel gefitinib derivatives incorporating the 1,2,3-triazole moiety were designed and synthesized. The synthesized compounds were evaluated for their potential anticancer activity against EGFR wild-type human non-small cell lu
Externí odkaz:
https://doaj.org/article/f84713dadc2c4faf94fc6075ebdfa619
Publikováno v:
Frontiers in Chemical Biology, Vol 3 (2024)
Maintaining cellular redox homeostasis is critical for cell viability and growth, with disruptions implicated in cellular responses to chemicals and drugs. This study investigates the interactions between acylfulvenes (AFs), a class of DNA alkylating
Externí odkaz:
https://doaj.org/article/b0fa27b5694e463abfed807a66329e43
Autor:
Yoshie Kametani, Ryoji Ito, Yoshiyuki Manabe, Jerzy K. Kulski, Toshiro Seki, Hitoshi Ishimoto, Takashi Shiina
Publikováno v:
Frontiers in Molecular Biosciences, Vol 11 (2024)
Immune-related drug delivery systems (DDSs) in humanized mouse models are at the forefront of cancer research and serve as bridges between preclinical studies and clinical applications. These systems offer unique platforms for exploring new therapies
Externí odkaz:
https://doaj.org/article/cb845f1c92344c21a0b2706a9396c0da
Publikováno v:
Thoracic Cancer, Vol 15, Iss 3, Pp 215-226 (2024)
Abstract Background Pyroptosis plays a pivotal role in the tumor immune microenvironment (TME) dynamics, particularly in non‐small cell lung cancer (NSCLC). The aim of our study was to explore its effects on tumor progression, TME patterns, and the
Externí odkaz:
https://doaj.org/article/79fee341e69540c9993a198205f9d6d7
Autor:
Cui Li, Jingmin Zhu, Linghan Shan, Yingyu Zhou, Gang Liu, Hong Zhu, Qunhong Wu, Yu Cui, Zheng Kang
Publikováno v:
BMC Health Services Research, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background The high costs of innovative anticancer drugs hinder a number of cancer patients’ access to these drugs in China. To address this problem, in 2018, the medical insurance access negotiation (MIAN) policy was implemented, when the
Externí odkaz:
https://doaj.org/article/7ed7938393984661a7251205577ed449